Click on a filter below to refine your search. Remove a filter to broaden your search.
Among outpatients with COVID-19 at high risk, the risk for hospitalization and death was reduced with the monoclonal antibody combo versus placebo.
A second study shows a reduction in the rate of death due to COVID-19 with a booster dose of BNT162b2 (Pfizer–BioNTech).
And patients on maintenance dialysis who received COVID-19 vaccination had decreasing antibody titers over time.
During a period of delta predominance, protection was lower among vaccinated persons without a previous COVID-19 diagnosis.